Epilepsy drugs levetiracetam and zonisamide should not be routinely used first line in the NHS, conclude researchers

Use of levetiracetam or zonisamide as first-line treatments in newly diagnosed focal epilepsy, or levetiracetam for newly diagnosed generalised epilepsy, is not supported by the results of two parallel, randomised, unblinded controlled trials. The SANAD II trials, published in Health Technology Assessment on 17 December 2021 and funded by the National Institute for Health Research, looked […]